Alright, let's talk about something that sounds like it's straight out of a sci-fi movie but is very much becoming a reality: gene-edited babies. We're not just talking about treating diseases in adults; we're talking about making changes that would pass down through generations. It's a huge topic, full of both incredible promise and deeply unsettling questions.
Recently, a West Coast biotech entrepreneur made headlines by announcing he's secured a whopping $30 million to launch a company focused on this very thing. That's a significant chunk of change, and it marks the biggest known investment yet into this incredibly controversial technology. So, what's going on, and why should we pay attention?
What Exactly Are We Talking About Here? Meet "Preventive"
The new company, called Preventive, isn't just a regular startup. It's actually a public-benefit company, which is a key detail we'll get into a bit later. Their core mission? To research what's called "heritable genome editing." Now, that's a bit of a mouthful, but let me break it down for you.
Basically, it means they want to explore modifying the DNA of embryos. Think about it: they'd either correct harmful mutations that cause diseases or, potentially, install beneficial genes right from the start. The big, overarching goal here is to prevent diseases before they even have a chance to develop. Lucas Harrington, a gene-editing scientist, is the one who founded Preventive, and he just laid out his plans in a recent blog post. He's been pretty clear that they're not rushing into anything. Instead, he says Preventive is all about "rigorously researching whether heritable genome editing can be done safely and responsibly." Sounds cautious, right? But the very idea itself is a huge deal.
Why This Is So Controversial: The Ethical Minefield
Here's the thing: creating genetically edited humans is super controversial. We've already seen what happens when someone jumps the gun. Remember the scientist in China who actually did this? He ended up imprisoned for three years. That's how serious this is. In fact, the procedure is still illegal in many countries, including right here in the US.
Beyond the legalities, there are serious doubts among many in the scientific and medical communities about how useful this really is as a form of medicine. We're talking about making permanent changes to the human germline – the genetic material that gets passed on. That's a huge responsibility, and many worry about unintended consequences that we can't even foresee yet.
The Temptation to "Shape" Humanity
But let's be honest, as gene-editing technology keeps racing forward, the temptation to somehow "shape" the future of our species could become incredibly strong. Especially for entrepreneurs who dream of putting their mark on the human condition. Imagine this: in theory, just small genetic tweaks could create people who are immune to heart disease or Alzheimer's, and those traits would then pass on to their children, and their children's children.
Harrington himself believes that if this technique proves safe, it "could become one of the most important health technologies of our time." He's even estimated that editing an embryo might only cost around $5,000, and he's banking on regulations potentially changing down the road. It's a bold vision, to say the least.
Not the Only Player: A Growing Trend?
Interestingly, Preventive isn't the only US startup this year to announce it's pursuing technology to create gene-edited babies. Nope, it's actually the third one.
First, there's Bootstrap Bio, based in California, which is reportedly looking for seed funding and apparently has an interest in enhancing intelligence. Yeah, you read that right – intelligence. Then there's Manhattan Genomics, also in the early stages, but they haven't announced any funding yet.
Now, it's important to keep these in perspective. As of right now, none of these companies have significant staff or facilities. And, perhaps most crucially, they largely lack any real credibility among mainstream gene-editing scientists. That's a big red flag for many.
The Scientific Community's Strong Reactions
So, how are established experts reacting to all this? Not well, in many cases. Take Fyodor Urnov, for example. He's a leading expert in gene editing at the University of California, Berkeley, where Lucas Harrington actually studied. When asked about these ventures, Urnov was pretty blunt, saying he believes they "should not move forward."
Urnov has been a vocal critic of heritable genome editing for a while now. He calls it dangerous, misguided, and a distraction from the real benefits of gene editing, which he sees in treating adults and children with existing conditions. In an email, he even shared his visceral reaction to the launch of yet another venture in this area: it made him want to "howl with pain." You can feel the frustration and concern in that, can't you? It's a stark contrast to the entrepreneurial excitement.
A Public-Benefit Mission? Looking Deeper at Preventive
Let's circle back to that "public-benefit company" detail. Preventive was incorporated in Delaware in May 2025 under the name Preventive Medicine PBC. The "PBC" stands for Public-Benefit Corporation, meaning it's legally structured to prioritize its public mission over pure profits.
Harrington emphasized this, writing in his post that "If our research shows [heritable genome editing] cannot be done safely, that conclusion is equally valuable to the scientific community and society." It's an interesting angle, suggesting they're committed to the science, even if it means proving their own concept is unsafe. It's a smart way to frame the research, especially given the controversy.
It's also worth noting that Harrington is a cofounder of Mammoth Biosciences, another gene-editing company that focuses on drugs for adults, and he still serves on their board. So, he's definitely got a background in this space.
Who's Backing This Venture? The Money Trail
Okay, so $30 million is a lot of money. But where's it coming from? Harrington says it was gathered from "private funders who share our commitment to pursuing this research responsibly." That's a pretty general statement, and he declined to identify these investors by name.
However, he did mention SciFounders, a venture firm he runs with his personal and business partner, Matt Krisiloff. Krisiloff is also the CEO of a biotech company called Conception, which is working on another potentially transformative (and controversial) technology: creating human eggs from stem cells. Krisiloff is also listed as a member of Preventive's founding team. So, it seems like a tight-knit circle of funding and development.
A Few Supporters (But Not Many Mainstream Scientists)
While mainstream gene-editing scientists seem largely skeptical, Preventive has managed to secure at least one endorsement. Paula Amato, a fertility doctor at Oregon Health Sciences University, has agreed to act as an advisor to the company.
Amato is part of a US team that's been researching embryo editing since 2017, and she's actually promoted the technology as a way to boost IVF success rates. Her idea is that if editing could correct abnormal embryos, it would make more viable ones available for women trying to get pregnant. That's a specific, potentially less controversial application, but it still involves embryo editing.
Still, it seems Preventive hasn't had much luck securing collaborations with other key research groups. And remember Urnov? He had some pretty harsh words for Manhattan Genomics when they reached out to him about working together: "I encourage you to stop," he wrote back. "You will cause zero good and formidable harm." That's a pretty strong stance, isn't it?
The Crypto Connection: A Surprising Alliance
Here's an unexpected twist in this whole story: the idea of edited babies has been getting a surprising amount of attention from figures in the cryptocurrency world.
Brian Armstrong, the billionaire founder of Coinbase, has reportedly hosted a series of off-the-record dinners to discuss this technology, and Harrington himself attended some of them. Armstrong has even publicly stated that "the time is right" for a startup venture in this area.
Another crypto entrepreneur, Will Harborne, a partner at LongGame Ventures, says he's "thrilled" about Preventive's launch. He believes that if the technology proves safe, "widespread adoption is inevitable," and he even calls its use a "societal obligation." Harborne's fund has actually invested in Herasight, a company that uses genetic tests to rank IVF embryos based on predicted future IQ and other traits. Now that's another hotly debated technology, but one that's already on the market because, surprisingly, such testing isn't strictly regulated.
The Bigger Picture: "Human Enhancement Companies" and What's Next
When you look at all these ventures together, it's easy to see why some people have started using the term "human enhancement companies." We're not just talking about curing disease anymore; we're talking about potentially selecting for, or even creating, specific traits.
What's really still missing from all this, though, is clear evidence that leading, mainstream gene-editing specialists are actually supporting these ventures. The skepticism and outright criticism from figures like Fyodor Urnov are hard to ignore.
Harrington, for his part, believes Preventive could help change these attitudes. He told MIT Technology Review earlier this year that "Most scientists I speak with either accept embryo editing as inevitable or are enthusiastic about the potential but hesitate to voice these opinions publicly." He hopes that being more public about this research will encourage others in the field to discuss it openly instead of just ignoring it. It's a fascinating and complex situation, where the drive for scientific advancement, entrepreneurial ambition, and profound ethical questions are all colliding. What happens next? We'll all be watching very closely.
